Pharma Industry Weighs In On EMA’s AI Regulation Proposals

Consistency and coherence with other relevant regulations should be a main priority for the European Medicines Agency when developing guidance on the use of artificial intelligence in the drug lifecycle, pharmaceutical industry representatives have said.

Pharma and medtech representatives gave their feedback on the European Medicines Agency’s proposed regulatory strategy for AI during a hybrid workshop this week, which saw hundreds of industry stakeholders assemble in-person and online.

Stephen Pyke, chief clinical data and digital officer for real-world evidence and AI innovation at the CRO Parexel, said during...